- Home
- BFRG vs GOVX Comparison
BFRG vs GOVX Comparison
Compare BFRG & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- GOVX
- Stock Information
- Founded
- BFRG 2017
- GOVX 2001
- Country
- BFRG United States
- GOVX United States
- Employees
- BFRG 17
- GOVX N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- GOVX Health Care
- Exchange
- BFRG Nasdaq
- GOVX Nasdaq
- Market Cap
- BFRG 15.4M
- GOVX 16.8M
- IPO Year
- BFRG 2023
- GOVX N/A
- Fundamental
- Price
- BFRG $1.49
- GOVX $0.54
- Analyst Decision
- BFRG
- GOVX Strong Buy
- Analyst Count
- BFRG 0
- GOVX 3
- Target Price
- BFRG N/A
- GOVX $10.67
- AVG Volume (30 Days)
- BFRG 139.3K
- GOVX 1.0M
- Earning Date
- BFRG 11-07-2025
- GOVX 11-11-2025
- Dividend Yield
- BFRG N/A
- GOVX N/A
- EPS Growth
- BFRG N/A
- GOVX N/A
- EPS
- BFRG N/A
- GOVX N/A
- Revenue
- BFRG $33,257.00
- GOVX $6,143,044.00
- Revenue This Year
- BFRG N/A
- GOVX N/A
- Revenue Next Year
- BFRG N/A
- GOVX N/A
- P/E Ratio
- BFRG N/A
- GOVX N/A
- Revenue Growth
- BFRG N/A
- GOVX 1943.07
- 52 Week Low
- BFRG $1.09
- GOVX $0.43
- 52 Week High
- BFRG $4.84
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- BFRG 59.62
- GOVX 36.98
- Support Level
- BFRG $1.32
- GOVX $0.46
- Resistance Level
- BFRG $1.53
- GOVX $0.59
- Average True Range (ATR)
- BFRG 0.10
- GOVX 0.04
- MACD
- BFRG 0.01
- GOVX -0.01
- Stochastic Oscillator
- BFRG 76.00
- GOVX 37.87
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.